Wellgistics Health (NASDAQ:WGRX - Get Free Report)'s stock had its "sell (e)" rating reissued by stock analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.
Separately, Wall Street Zen cut Wellgistics Health from a "hold" rating to a "sell" rating in a research note on Saturday, September 13th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Wellgistics Health has a consensus rating of "Sell".
Check Out Our Latest Stock Analysis on Wellgistics Health
Wellgistics Health Stock Down 2.7%
Shares of NASDAQ WGRX traded down $0.02 during trading hours on Wednesday, hitting $0.70. The company's stock had a trading volume of 381,631 shares, compared to its average volume of 1,552,290. The company has a debt-to-equity ratio of 11.16, a current ratio of 0.32 and a quick ratio of 0.11. Wellgistics Health has a 12 month low of $0.62 and a 12 month high of $7.04. The stock has a 50-day moving average price of $1.07.
Wellgistics Health (NASDAQ:WGRX - Get Free Report) last posted its earnings results on Tuesday, August 19th. The company reported ($0.11) earnings per share (EPS) for the quarter. The company had revenue of $7.79 million during the quarter.
Wellgistics Health Company Profile
(
Get Free Report)
Founded in 2022, Wellgistics Health is a holding company for various existing and planned strategic businesses centered around pharmaceuticals and healthcare services. As a micro health ecosystem, our portfolio of companies consists of a pharmacy, wholesale operations, and a technology division with a novel platform for hub and clinical services.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Wellgistics Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Wellgistics Health wasn't on the list.
While Wellgistics Health currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
